Checkpoint inhibitors in bladder and renal cancers: Results and perspectives

Immunotherapy

Volumn 7, Issue 12, 2015, Pages 1259-1271

  Aoun, Fouad ^a   Kourie, Hampig R ^a   Sideris, Spyridon ^a   Roumeguère, Thierry ^b   Velthoven, Roland Van ^a   Gil, Thierry ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

bladder cancer; checkpoint inhibitors; CTLA4; immunotherapy; PD1 PDL1; renal cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; BEVACIZUMAB; BMS 936559; EVEROLIMUS; IPILIMUMAB; NIVOLUMAB; PAZOPANIB; PEMBROLIZUMAB; SUNITINIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ADVANCED CANCER; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; DRUG MECHANISM; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CELL CYCLE CHECKPOINT; CYTOTOXIC T LYMPHOCYTE; DRUG RESISTANCE; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY NEOPLASMS; PROCEDURES; URINARY BLADDER NEOPLASMS;

ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL CYCLE CHECKPOINTS; CTLA-4 ANTIGEN; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, CYTOTOXIC; URINARY BLADDER NEOPLASMS;

EID: 84949009874     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.91     Document Type: Review

References (65)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
2. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability: an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11(3), 220-228 (2010).
3. Salk JJ, Fox EJ, Loeb LA. Mutational heterogeneity in human cancers: origin and consequences. Annu. Rev. Pathol. 5, 51-75 (2010).
4. Coffelt SB, Lewis CE, Naldini L et al.Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am. J. Pathol. 176(4), 1564-1576 (2010).
5. Denardo DG, Andreu P, Coussens LM. Interactions between lymphocytes and myeloid cells regulate pro-versus antitumor immunity. Cancer Metastasis Rev. 29(2), 309-316 (2010).
6. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 31(6), 220-227 (2010).
7. Shields JD, Kourtis IC, Tomei AA et al.Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328(5979), 749-752 (2010).
8. Mougiakakos D, Choudhury A, Lladser A et al.Regulatory T cells in cancer. Adv. Cancer Res. 107 57-117 (2010).
9. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182(8), 4499-4506 (2009).
10. Devita VT Jr., Rosenberg SA. Two hundred years of cancer research. N. Engl. J. Med. 366(23), 2207-2214 (2012).
11. Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. Eur. J. Pharmacol. 625(1-3), 41-54 (2009).
12. Dunn GP, Bruce AT, Ikeda H et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3(11), 991-998 (2002).
13. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252-264 (2012).
14. Blank CU. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. Curr. Opin. Oncol. 26(2), 204-214 (2014).
15. Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr. Opin. Pharmacol. 23 32-38 (2015).
16. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin. Cancer Res. 17(22), 6958-6962 (2011).
17. Selby MJ, Engelhardt JJ, Quigley M et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 1(1), 32-42 (2013).
18. Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J. Leukoc. Biol. 94(1), 25-39 (2013).
19. Pentcheva-Hoang T, Simpson TR, Montalvo-Ortiz W, Allison JP. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanomaspecific T-cell motility. Cancer Immunol. Res. 2(10), 970-980 (2014).
20. Fyfe G, Fisher RI, Rosenberg SA et al.Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13(3), 688-696 (1995).
21. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N. Engl. J. Med. 338(18), 1272-1278 (1998).
22. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007).
23. Escudier B, Bellmunt J, Negrier S et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 28(13), 2144-2150 (2010).
24. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26(33), 5422-5428 (2008).
25. Blansfield JA, Beck KE, Tran K et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J. Immunother. 28(6), 593-598 (2005).
26. Beck KE, Blansfield JA, Tran KQ et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 24(15), 2283-2289 (2006).
27. Yang JC, Hughes M, Kammula U et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30(8), 825-830 (2007).
28. Rini BI, Stein M, Shannon P et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 117(4), 758-767 (2011).
29. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
30. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167-3175 (2010).
31. Cho BC, Sosman JA, Sznol M et al. Clinical activity, safety, and biomarkers of 552 MPDL3280A, an engineered PD-L1 antibody inpatients with metastatic renal cell 553 carcinoma (mRCC). J. Clin. Oncol. 31, Abstract 4505 (2013).
32. Mcdermott DF, Drake CG, Sznol M et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J. Clin. Oncol. 33(18), 2013-2020 (2015).
33. Motzer RJ, Rini BI, Mcdermott DF et al. nivolumab for metastatic renal cell carcinoma: results of a randomized Phase II trial. J. Clin. Oncol. 33(13), 1430-1437 (2015).
34. Mcdermott DF, Sznol M, Sosman JA et al. Immune correlates and long term follow 567 up of a Phase Ia study of MPDL3280A, an engineered PD-L1 antibody, in patients with 568 metastatic renal cell carcinoma. Ann. Oncol. (S4), Abstract 8090 (2014).
35. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 73(12), 3591-3603 (2013).
36. Hammers HJ, Plimack ER, Infante JR et al. Phase I study of nivolumab in 576 combination with ipilimumab in metastatic renal cell carcinoma. J. Clin. Oncol. 32(S35), 577 Abstract 4504 (2014).
37. Amin A, Plimack ER, Infante JR et al. Nivolumab in combination with sunitinib or 579 pazopanib in patients with metastatic renal cellcarcinoma. Ann. Oncol. 25(Suppl. 24), 580, iv362-iv583 (2014).
38. Babaian RJ, Johnson DE, Llamas L, Ayala AG. Metastases from transitional cell carcinoma of urinary bladder. Urology 16(2), 142-144 (1980).
39. Harker WG, Meyers FJ, Freiha FS et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J. Clin. Oncol. 3(11), 1463-1470 (1985).
40. Sternberg CN, Yagoda A, Scher HI et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J. Urol. 133(3), 403-407 (1985).
41. Shelley MD, Court JB, Kynaston H et al. Intravesical Bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst. Rev. doi:10.1002/14651858 (2000) (Epub ahead of print).
42. Inamoto T, Azuma H. Immunotherapy of genitourinary malignancies. J. Oncol. 2012, 397267 (2012).
43. Wu Y, Enting D, Rudman S, Chowdhury S. Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond. Expert Rev. Anticancer Ther. 15(5), 509-523 (2015).
44. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492), 315-322 (2014).
45. Wang L, Su G, Zhao X et al. Association between the cytotoxic T-lymphocyte antigen 4 +49A/G polymorphism and bladder cancer risk. Tumour Biol. 35(2), 1139-1142 (2014).
46. Carthon BC, Wolchok JD, Yuan J et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res. 16(10), 2861-2871 (2010).
47. Chen DS, Irving BA, Hodi FS. Molecular pathways: nextgeneration immunotherapy-inhibiting programmed deathligand 1 and programmed death-1. Clin. Cancer Res. 18(24), 6580-6587 (2012).
48. Plimack ER, Gupta S, Bellmunt J et al. Phase 1B study of pembrolizumab (pembro; MK-3475) in patients (pts) with advanced urothelial tract cancer. Ann. Oncol. 25(LBA23A) (2014).
49. Powles T, Eder JP, Fine GD et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528), 558-562 (2014).
50. Rouas-Freiss N, Moreau P, Lemaoult J, Carosella ED. The dual role of HLA-G in cancer. J. Immunol. Res. 2014, 359748 (2014).
51. Lin A, Zhang X, Xu HH et al. HLA-G expression is associated with metastasis and poor survival in the Balb/c nu/nu murine tumor model with ovarian cancer. Int. J. Cancer 131(1), 150-157 (2012).
52. Kren L, Valkovsky I, Dolezel J et al. HLA-G and HLA-E specific mRNAs connote opposite prognostic significance in renal cell carcinoma. Diagn. Pathol. 7(58), 58-65 (2012).
53. Brunner A, Hinterholzer S, Riss P et al. Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis. Gynecol. Oncol. 124(1), 105-111 (2012).
54. Chen YW, Tekle C, Fodstad O. The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion. Curr. Cancer Drug Targets 8(5), 404-413 (2008).
55. Qin X, Zhang H, Ye D et al. B7-H3 is a new cancer-specific endothelial marker in clear cell renal cell carcinoma. Onco. Targets Ther. 6 1667-1673 (2013).
56. Crispen PL, Sheinin Y, Roth TJ et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin. Cancer Res. 14(16), 5150-5157 (2008).
57. Krambeck AE, Dong H, Thompson RH et al. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin. Cancer Res. 13(6), 1749-1756 (2007).
58. Norde WJ, Hobo W, Van Der Voort R, Dolstra H. Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. Blood 120(4), 728-736 (2012).
59. Brignone C, Escudier B, Grygar C et al. A Phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin. Cancer Res. 15(19), 6225-6231 (2009).
60. Ngiow SF, Teng MW, Smyth MJ. Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res. 71(21), 6567-6571 (2011).
61. Cai C, Xu YF, Wu ZJ et al. Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma. World J. Urol. doi:10.1007/s00345-015-1656-1657 (2015) (Epub ahead of print).
62. Yang M, Yu Q, Liu J et al. T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: clinicopathologic correlations and association with survival. J. Surg. Oncol. doi:10.1002/jso.24012 (2015) (Epub ahead of print).
63. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373(2), 123-135 (2015).
64. Weber JS, D'angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Phase 3 trial. Lancet Oncol. 16(4), 375-384 (2015).
65. Gunturi A, Mcdermott DF. Nivolumab for the treatment of cancer. Expert Opin. Investing. Drugs 24(2), 253-260 (2015).